Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:

Tuesday, April 24, 2018

Are Stem Cells the Next Generation of Stroke Therapeutics?

Going for a moonshot rather than tackling the solvable problems in stroke or the 5 causes of the neuronal cascade of death
This crapola is why stroke survivors need to be in charge.

Sean I. Savitz
Stroke. 2018;49:1056-1057
Originally published April 18, 2018

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

In this exciting atmosphere of having new endovascular treatment options for our acute stroke patients, the Stroke journal commissioned a focused update on the application of stem cells and cell-based therapies given new advancements in our mechanistic understanding of stem cells and given the launch of phase 2B and 3 efficacy trials. After initial attempts in cell transplantation approaches for patients with chronic subcortical strokes in the 1990s, the field of stem cells in stroke shifted focus over the past 20 years, resulting in new therapeutic strategies using easily accessible cell types that modulate immune responses to injury and amplify endogenous repair processes. We have learned that the secretomes and microparticles that cell therapies release may be the principal mediators of their therapeutic effects.
Partnerships between industry and academia have been instrumental in advancing this field. Only a select few companies have sustained investments to carry out studies from preclinical development all the way to efficacy trials. Notably, Athersys has initiated two phase 3 efficacy trials on its cell-based platform, MultiStem, for patients with acute ischemic stroke, whereas ReNeuron and SanBio are now in phase 2B stages for patients with chronic stroke.
In this focused update, we …
View Full Text

No comments:

Post a Comment